Foreign Filer Report • Dec 6, 2024
Preview not available for this file type.
Download Source File6-K 1 f6k_120624.htm FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____
FORM 6-K
____
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
December 6, 2024
____
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
____
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
Field: Page; Sequence: 1
Field: /Page
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk’s subsequent acquisition of three manufacturing sites from Novo Holdings A/S.
The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here.
On 29 May 2024, Catalent stockholders voted to approve the pending transaction. Moreover, the acquisition has been approved by the authorities in a number of jurisdictions.
The completion of the acquisition remains subject to the fulfilment of further customary closing conditions, including regulatory approvals in other jurisdictions. Novo Nordisk still expects the acquisition to be completed towards the end of 2024.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
| Novo Nordisk A/S Investor Relations |
|---|
| Company announcement No 93 / 2024 |
Field: Page; Sequence: 2
Field: /Page
Contacts for further information
| Media: | |
|---|---|
| Ambre James-Brown +45 3079 9289 [email protected] | Liz Skrbkova (US) +1 609 917 0632 [email protected] |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 [email protected] | David Heiberg Landsted +45 3077 6915 [email protected] |
| Sina Meyer +45 3079 6656 [email protected] | Ida Schaap Melvold +45 3077 5649 [email protected] |
| Frederik Taylor Pitter +1 609 613 0568 [email protected] |
| Novo Nordisk A/S Investor Relations |
|---|
| Company announcement No 93 / 2024 |
Field: Page; Sequence: 3
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: December 6, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.